A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: Results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau)

BJU International

Volumn 117, Issue 4, 2016, Pages 576-583

  Randazzo, Marco ^a,b   Müller, Alexander ^a   Carlsson, Sigrid ^c,d   Eberli, Daniel ^a   Huber, Andreas ^b   Grobholz, Rainer ^b   Manka, Lukas ^e   Mortezavi, Ashkan ^a   Sulser, Tullio ^a   Recker, Franz ^b   Kwiatkowski, Maciej ^b,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Academic Hospital Braunschweig   (Germany)

Author keywords

positive family history; prostate cancer aggressiveness; prostate cancer screening; prostate specific antigen; screening intensity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; AGED; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; GENETICS; INCIDENCE; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; PEDIGREE; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SWITZERLAND;

AGED; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PEDIGREE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SWITZERLAND;

EID: 84960429348     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13310     Document Type: Article

References (36)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
3. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-35
4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78
5. Jahn JL, Giovannucci EL, Stampfer MJ,. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-Specific Antigen-Era. Int J Cancer 2014. doi: 10.1002/ijc.29408. [Epub ahead of print]
6. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI,. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012; 36: 1346-52
7. Randazzo M, Beatrice J, Huber A, et al. Is further screening of men with baseline PSA < 1 ng ml worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). Int J Cancer 2015; 137: 553-9
8. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer, EAU 2013. Available at: http://www.uroweb.org/guidelines/online-guidelines/?no-cache=1. Accessed September 2015
9. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419-26
10. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85
11. Frank C, Fallah M, Ji J, Sundquist J, Hemminki K,. The population impact of familial cancer, a major cause of cancer. Int J Cancer 2014; 134: 1899-906
12. Brandt A, Bermejo JL, Sundquist J, Hemminki K,. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 2010; 58: 275-80
13. Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H,. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013; 63: 419-25
14. Howard K, Brenner AT, Lewis C, et al. A comparison of US and Australian men's values and preferences for PSA screening. BMC Health Serv Res 2013; 13: 388
15. Glass AS, Cowan JE, Fuldeore MJ, et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology 2013; 82: 60-5
16. Selkirk CG, Wang CH, Lapin B, Helfand BT,. Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease. Urology 2015; 85: 742-7
17. Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA,. Aggressiveness of familial prostate cancer. J Clin Oncol 2006; 24: 3445-50
18. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC,. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-8
19. Bratt O, Garmo H, Adolfsson J, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010; 102: 1336-43
20. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34
21. Kwiatkowski M, Huber A, Stamm B, et al. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003; 92 (Suppl. 2): 44-7
22. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
23. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R,. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166: 851-5
24. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
25. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
26. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ,. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med 2006; 8: 571-5
27. Mai PL, Wideroff L, Greene MH, Graubard BI,. Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study. Public Health Genomics 2010; 13: 495-503
28. Saarimaki L, Tammela TL, Maattanen L, et al. Family history in the Finnish Prostate Cancer Screening Trial. Int J Cancer 2015; 136: 2172-7
29. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P,. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107: 797-803
30. Johns LE, Houlston RS,. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-94
31. Thomas JA 2nd, Gerber L, Moreira DM, et al. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 2012; 272: 85-92
32. Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ,. Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006; 176: 2438-42
33. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML,. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 2006; 176: 1118-21
34. Van der Meer S, Löwik SA, Hirdes WH, et al. Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. BMC Fam Pract 2012; 13: 100
35. Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT,. A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. BJU Int 2015; 115: 101-5
36. Beebe-Dimmer JL, Isaacs WB, Zuhlke KA, et al. Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. BJU Int 2014; 113: 830-5